<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Press Coverage Lung Cancer

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Default sub title

Author OncLive | Publish Date July 27, 2020

Paul A. Bunn, Jr, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC).

Comments